Success Metrics

Clinical Success Rate
70.0%

Based on 77 completed trials

Completion Rate
70%(77/110)
Active Trials
39(24%)
Results Posted
90%(69 trials)
Terminated
33(20%)

Phase Distribution

Ph not_applicable
13
8%
Ph phase_1
58
36%
Ph phase_3
14
9%
Ph phase_4
1
1%
Ph early_phase_1
4
2%
Ph phase_2
72
44%

Phase Distribution

62

Early Stage

72

Mid Stage

15

Late Stage

Phase Distribution162 total trials
Early Phase 1First-in-human
4(2.5%)
Phase 1Safety & dosage
58(35.8%)
Phase 2Efficacy & side effects
72(44.4%)
Phase 3Large-scale testing
14(8.6%)
Phase 4Post-market surveillance
1(0.6%)
N/ANon-phased studies
13(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.8%

77 of 117 finished

Non-Completion Rate

34.2%

40 ended early

Currently Active

39

trials recruiting

Total Trials

163

all time

Status Distribution
Active(39)
Completed(77)
Terminated(40)
Other(7)

Detailed Status

Completed77
Terminated33
Recruiting22
Active, not recruiting17
Withdrawn7
unknown6

Development Timeline

Analytics

Development Status

Total Trials
163
Active
39
Success Rate
70.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.5%)
Phase 158 (35.8%)
Phase 272 (44.4%)
Phase 314 (8.6%)
Phase 41 (0.6%)
N/A13 (8.0%)

Trials by Status

terminated3320%
unknown64%
completed7747%
withdrawn74%
recruiting2213%
active_not_recruiting1710%
suspended11%

Recent Activity

Clinical Trials (163)

Showing 20 of 163 trialsScroll for more
NCT04684368Phase 2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting
NCT01857934Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Completed
NCT02436707Phase 2

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active Not Recruiting
NCT06345495Phase 2

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Recruiting
NCT03577431Phase 1

Liver Transplantation With Tregs at MGH

Completed
NCT04558736Phase 2

Haploidentical HCT for Severe Aplastic Anemia

Recruiting
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT05436418Phase 1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting
NCT05470283Phase 1

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active Not Recruiting
NCT05813327Phase 1

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Terminated
NCT07428993Phase 2

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Recruiting
NCT04881240Phase 1

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Recruiting
NCT07257419Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting
NCT04530565Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active Not Recruiting
NCT06834282Phase 1

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Recruiting
NCT06001385Phase 2

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Active Not Recruiting
NCT03630211Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting
NCT00338377Phase 2

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active Not Recruiting
NCT03573700Phase 1

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT04947501Early Phase 1

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
163